Levodopa Carbidopa Intestinal Gel for Parkinson’s Disease over 11 years: A Single Center “Real-World” Experience
Objective: To review long-term real-world experience and clinical outcomes in PD patients with LCIG therapy over 11 years in a multidisciplinary University clinic setting. Background:…Determinants of quality of life and daily mobility in Parkinson’s disease: the role of fear of falling.
Objective: We aimed to investigate the relationship between the PD clinical features, the presence of FOF and its impact on QoL. We explored whether the…Use of the Dysphagia Handicap Index (DHI) patient reported outcomes measure in Parkinson disease and cervical dystonia
Objective: Objective: To demonstrate the value of using the DHI in movement disorders clinics. Background: Background: Dysphagia has a negative effect on work, leisure, and…Subacute Encephalopathy with Seizures in Alcohol Consumers (SESA) presenting as Focal Dyskinesias and Myoclonus
Objective: The purpose of this case series is to describe the clinical and electrophysiological features of SESA syndrome presenting as focal seizures mimicking dyskinesias and…Resolving missing data from the MDS-UPDRS: implications for telemedicine
Objective: The aim of this study was to determine imputation accuracy for total-sum and item-specific MDS-UPDRS Part III (Motor Examination) scores in remote administration. Background:…Characteristics of Pain in Parkinson’s Disease with Arabic translation and validation of King’s Parkinson’s Disease Pain Scale
Objective: To translate and validate the King’s Parkinson’s Disease Pain Scale (KPPS) into Arabic and to correlate pain among PD patients with motor and non-motor…A strategic training framework for building research capacity in the Global Parkinson’s Genetics Program (GP2)
Objective: To promote and facilitate learning internationally with resources and expertise to serve the training needs of the Global Parkinson’s Genetics Program (GP2;www.gp2.org) and its…Dopamine dysregulation syndrome in Parkinson’s disease controlled by safinamine
Objective: To describe a case of dopamine dysregulation syndrome managed by safinamide. Background: Dopamine dysregulation syndrome (DDS) is an uncommon non-motor symptom of Parkinson disease…Atypical parkinsonism and psychiatric disorder in hereditary diffuse leukoencephalopathy with spheroids: a novel variant in the CSF1R gene
Objective: We describe the clinical, radiological and neuropathological phenotype of a patient carrying a novel variant in the CSF1R gene. Background: Hereditary diffuse leukoencephalopathy with…Long-term dementia prevalence in Parkinson disease: Glass half-full?
Objective: To determine long-term, cumulative dementia prevalence rates in Parkinson disease (PD) using data from two large, ongoing, prospective observational studies. Background: Dementia is reported to occur in…
- « Previous Page
- 1
- …
- 176
- 177
- 178
- 179
- 180
- …
- 186
- Next Page »